Lisanti Capital Growth LLC Takes $1.59 Million Position in Guardant Health, Inc. $GH
Lisanti Capital Growth LLC has acquired a new stake of 10,610 shares in Guardant Health, Inc. (NASDAQ:GH) during the second quarter, valued at approximately $1.59 million. This move is part of a broader trend of institutional investment in Guardant Health, with several other large investors also either adding to or initiating positions in the company. Despite significant insider selling activity, analysts have largely maintained "buy" or "outperform" ratings, with an average price target of $183.78 for the stock.
MSH Capital Advisors LLC Purchases Shares of 6,242 Guardant Health, Inc. $GH
MSH Capital Advisors LLC initiated a new position in Guardant Health (NASDAQ:GH) during the second quarter, acquiring 6,242 shares valued at approximately $936,000. Institutional investors now collectively own 92.60% of the company, though insiders have recently sold a significant number of shares. Despite insider sales, analysts maintain a "Moderate Buy" rating with an average price target of $183.78, supported by the company's strong Q2 revenue growth of 44.3% year-over-year.
Eagle Health Investments LP Acquires New Position in Guardant Health, Inc. $GH
Eagle Health Investments LP has acquired a new position in Guardant Health, Inc. (NASDAQ:GH) during the second quarter, purchasing 300,685 shares valued at approximately $45.11 million. This investment makes Guardant Health the third-largest position in Eagle Health Investments LP's portfolio, comprising 7.5% of its holdings. Other institutional investors also initiated new stakes in Guardant Health, while company insiders, including Chris Freeman and CEO Amirali Talasaz, sold significant shares.
How Investors Are Reacting To Guardant Health (GH) Expanding Blood-Based Cancer Screening Acceptance
Guardant Health (GH) has seen significant advancements with FDA approval for its Guardant360 test and inclusion of its Shield colorectal cancer screening test in American Cancer Society guidelines. These developments indicate growing acceptance of Guardant's blood-based cancer tests, influencing its investment narrative positively. While these milestones support broader adoption, the company still faces challenges related to cash burn and potential future financing needs.
7,149 Shares in Guardant Health, Inc. $GH Purchased by Perigon Wealth Management LLC
Perigon Wealth Management LLC has acquired 7,149 shares of Guardant Health, Inc. (NASDAQ:GH), valued at approximately $1.07 million, contributing to institutional investors owning 92.6% of the company. Despite significant insider selling totaling over $80 million, Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $183.78, following Guardant Health's strong quarterly revenue growth and narrower-than-expected loss.
Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 116 Shares of Stock
Guardant Health (NASDAQ:GH) Director Musa Tariq sold 116 shares of the company's stock for $18,148.20 on August 17th, reducing his stake by 1.01%. This transaction occurred under a pre-arranged Rule 10b5-1 plan. The company's shares traded down 1.0% to $160.12, despite beating analyst expectations for its latest quarterly revenue and adjusted loss per share, and analysts generally maintain a "Moderate Buy" rating for the stock.
How Guardant aims to expand cancer screening with a blood test
Guardant Health is making strides in early cancer detection with its Shield blood test for colorectal cancer, which gained FDA approval in 2024 and is being covered by UnitedHealthcare. The company is actively working to improve the test's sensitivity, particularly for early-stage cancers and precancerous lesions, and is expanding its application to multicancer detection. Guardant aims to eventually pursue FDA approval for its multicancer test, building on its current status as a lab-developed test gathering real-world evidence.
Guardant Health (GH) Back In Focus As New Approvals Put Valuation To The Test
Guardant Health (GH) has re-entered investor focus following Q2 2026 developments, including FDA approval for its Guardant360 liquid biopsy test and American Cancer Society support for its Shield colorectal cancer screening. The company's stock has seen significant gains, with a 64.65% return over 90 days and 171.85% over the past year. While a popular narrative suggests the stock is 6% undervalued with a fair value of $171 per share, its current P/S ratio of 18.3x is considerably higher than the US Healthcare industry average of 1.5x, raising valuation risk concerns.
Guardant Health (NASDAQ: GH) insider plans August sale of 116 shares
Musa Tariq, an insider at Guardant Health, Inc. (NASDAQ: GH), has filed a Form 144 notice to sell 116 shares of common stock, valued at $18,148.00, on or after August 17, 2026. These shares originated from a Restricted Stock Lapse related to equity compensation on July 15, 2026. The filing also details several prior sales of Guardant Health stock by Tariq over the preceding three months.
GSA Capital Partners LLP Makes New $1.77 Million Investment in Guardant Health, Inc. $GH
GSA Capital Partners LLP has made a new investment of $1.77 million in Guardant Health, Inc. by purchasing 11,811 shares during the second quarter. Despite significant insider selling totaling over $106 million in the last three months, institutional investors collectively own 92.60% of the company. Guardant Health maintains a "Moderate Buy" consensus rating from analysts, with several firms raising their price targets, indicating a positive outlook for the company's stock.
SWS Partners Makes New Investment in Guardant Health, Inc. $GH
SWS Partners has acquired a new stake in Guardant Health, Inc. (NASDAQ:GH), purchasing 74,582 shares valued at approximately $11.19 million, making it their 9th largest position. While institutional investors collectively own 92.6% of the company, several insiders have recently sold shares totaling over $106 million. Analysts maintain a "Moderate Buy" rating with an average price target of $183.78 for Guardant Health.
Guardant Health CPO Monroe sells $7.6 million in stock
Guardant Health's Chief People Officer, Terilyn J. Monroe, sold approximately $7.6 million worth of company stock after exercising options. The sale involved 46,300 shares, following a significant 172% return for Guardant Health stock over the past year. This transaction occurred amidst strong second-quarter results for the company, which saw a 44% revenue growth and subsequent price target raises from multiple analyst firms.
Guardant Health(GH.US) Officer Sells US$7.65 Million in Common Stock
An officer at Guardant Health (GH.US) recently sold a significant amount of common stock, totaling US$7.65 million. This transaction provides insight into insider activity at the company. Further details regarding the sale, such as the number of shares and price per share, would be in the full article.
T. Rowe Price discloses 4.9% Guardant Health (GH) holding in 13G/A
T. Rowe Price Associates, Inc. has filed a Schedule 13G/A, disclosing a 4.9% beneficial ownership in Guardant Health, Inc. (GH) as of June 30, 2026. The firm holds 6,514,828 shares, with sole voting power over 6,359,951 shares and sole dispositive power over all 6,514,828 shares. T. Rowe Price explicitly denies that this filing constitutes an admission of beneficial ownership.
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate
Guardant Health reported accelerated growth in its oncology testing, minimal residual disease (MRD), and colorectal cancer screening businesses, with significant year-over-year increases in revenue for Guardant360 and Guardant Reveal. The company plans to launch its tumor-informed Reveal Ultra test in 2026 and expects a 15% reduction in Shield's cost of goods sold by year-end. Guardant is also pursuing broader reimbursement, ADLT status for key tests, and potential expansion of Shield into lung and multi-cancer detection.
Guardant Health Insider Sold Shares Worth $7,645,218, According to a Recent SEC Filing
Terilyn J. Monroe, Chief People Officer at Guardant Health, sold 46,300 shares of the company's stock on August 12, 2026. The total value of these shares amounted to $7,645,218. This transaction was disclosed in a recent SEC filing.
Guardant Health CPO Monroe sells $7.6 million in stock
Guardant Health Chief People Officer Terilyn J. Monroe sold approximately $7.6 million worth of company stock on August 12, 2026, after exercising stock options. These sales followed a significant 172% return for Guardant Health stock over the past year. The transactions occurred amidst strong financial performance for the company, including a 44% year-over-year revenue growth in the second quarter, leading several analysts to raise their price targets.
Guardant Health, Inc. SEC Filing (Aug 12, 2026)
Guardant Health, Inc. filed a Form 144 with the SEC on August 12, 2026, detailing a proposed sale of 46,300 common shares acquired through employee stock option exercise. The aggregate market value of these securities to be sold is $7,645,219.00, with Charles Schwab & Co., Inc. listed as the broker.
Guardant Health CCO Chris Freeman sells $10.7m in common stock
Chris Freeman, CCO of Guardant Health (NASDAQ:GH), sold 63,605 shares of common stock for approximately $10.7 million on August 10, 2026, after exercising stock options. The sale occurred as the stock trades near its 52-week high, following a significant 200% gain over the past year. This news follows Guardant Health's strong Q2 earnings report, which led to upward revisions in price targets from several analyst firms.
Guardant Health sees strong growth from MRD and screening, boosted by FDA approvals and guideline inclusion.
Guardant Health is experiencing significant growth in its minimal residual disease (MRD) and cancer screening sectors, fueled by recent FDA approvals, increased insurance coverage, and inclusion in clinical guidelines. While competition is expected to intensify, the company is still projected to deliver solid returns despite a less favorable risk-return profile due to its stock price gains.
Guardant Health grants 46,044 RSUs to 149 new employees under inducement plan
Guardant Health has granted 46,044 Restricted Stock Units (RSUs) to 149 new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The grants were made on August 3, 2026, and will vest in three equal annual installments, contingent on continued employment. This news brief was generated by AI based on content published by Guardant Health Inc. via Business Wire.
Guardant Health (GH) holder plans 63,605-share stock resale
A Guardant Health (GH) shareholder, Chris Freeman, plans to resell up to 63,605 common shares through Charles Schwab & Co., Inc. The aggregate market value of these shares is $10,786,111.00, and the sale is linked to a cashless employee stock option exercise on August 10, 2026. This filing also discloses a previous sale of 24,406 Guardant Health shares by Freeman on May 22, 2026, totaling $2,896,361.00.
How Guardant Health Inc. (GH) Affects Rotational Strategy Timing
This article analyzes Guardant Health Inc. (GH) using AI models to provide trading strategies and signal analysis. It indicates strong sentiment for GH across all horizons, supporting an overweight bias, and outlines specific position, momentum, and risk-hedging strategies with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for the stock.
How Guardant Health Inc. (GH) Affects Rotational Strategy Timing
This article analyzes Guardant Health Inc. (GH) with a focus on its impact on rotational strategy timing. It highlights strong sentiment supporting an overweight bias, outlines institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels, and provides multi-timeframe signal analysis indicating strong signals across near-term, mid-term, and long-term horizons.
Guardant Health (GH) Is Up 6.1% After Raising 2026 Revenue Outlook And Filing Shelf Registration - Has The Bull Case Changed?
Guardant Health (GH) saw its stock rise 6.1% after increasing its 2026 revenue guidance to US$1.34–1.36 billion, driven by accelerated Shield screening adoption and new UnitedHealth coverage. While the raised outlook strengthens the bull case for sales growth, the company also filed a shelf registration, indicating a potential for future financing, which could lead to dilution if net losses persist. The article suggests that while sales are up, continued losses mean the core investment narrative remains largely unchanged, albeit with a stronger near-term catalyst in Shield adoption.
Guardant Health (GH) Following Earnings And Higher Guidance Has Valuation Back In Focus
Guardant Health (GH) recently released its second-quarter 2026 results, reporting higher sales but a wider net loss, while raising its full-year revenue guidance. The company also filed a broad shelf registration for future financing. Despite a strong stock performance over the past year, its current P/S ratio of 19.1x significantly exceeds the industry average, raising questions about whether its growth and margin story can justify such a premium.
Dimensional Fund Advisors LP Sells 123,826 Shares of Guardant Health, Inc. $GH
Dimensional Fund Advisors LP reduced its stake in Guardant Health, Inc. by 40.4% in the first quarter, selling 123,826 shares. Despite this and significant insider selling, Guardant Health's stock price rose 6.9% to $168.48, near its 12-month high, reflecting a "Moderate Buy" consensus from analysts with an average price target of $183.78. Institutional investors collectively own a substantial 92.6% of the company.
Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Moderate Buy" by Analysts
Analysts have assigned Guardant Health, Inc. (NASDAQ:GH) an average rating of "Moderate Buy," with a consensus 12-month price target of $183.78 among 25 analysts. Several firms recently raised their price targets, indicating continued bullish sentiment. Despite insider selling, institutional investors hold a significant stake in the company, which specializes in blood-based cancer diagnostics.
Guardant Health (GH) Q2 2026 Earnings Call Transcript
Guardant Health (GH) reported strong Q2 2026 earnings with a 44% year-over-year revenue growth, driven by its Oncology, Biopharma & Data, and Screening segments. Key milestones included FDA approval for Guardant360 Liquid CDx and a higher-throughput Shield workflow, along with Shield's inclusion in American Cancer Society guidelines and coverage by UnitedHealth Group. The company raised its full-year revenue guidance and is focused on expanding market penetration, reducing costs, and achieving cash flow breakeven by the end of 2027.
Guardant Health co-CEO Helmy Eltoukhy sells $12.6m in stock
Guardant Health co-CEO Helmy Eltoukhy sold approximately $12.6 million worth of common stock on June 5, 2026, through his revocable trust. The sale involved 90,000 shares at prices ranging from $125.569 to $132.55, occurring as the stock trades near its 52-week high after a 160% return. Despite this insider sale and an InvestingPro analysis suggesting overvaluation, several analyst firms have recently raised price targets and maintained positive ratings due to FDA approvals and new screening guideline recommendations for Guardant Health's products.
Guardant Health director Manuel Hidalgo Medina sells $279k in stock
Guardant Health director Manuel Hidalgo Medina recently sold approximately $279,201 worth of stock, while also acquiring shares valued at $30,922 through stock options. These transactions occurred as the company's stock trades near its 52-week high, having seen a 266% return over the past year. The sales and acquisitions are detailed in a Form 4 filing, alongside information about Guardant Health's strong second-quarter results and increased revenue guidance, leading to positive analyst reactions.
Guardant Health (GH) Stock May Be Below Fair Value After Raised Guidance
Guardant Health's stock has shown strong returns, but its valuation presents a mixed picture. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 24.1%, implying an intrinsic value of $215 per share, its Price-to-Sales (P/S) ratio of 18.5x is significantly higher than the industry average, indicating overvaluation. The article highlights that the ongoing debate revolves around the weight given to future free cash flow improvement versus current revenue multiples, especially given the company's Q2 revenue update and raised full-year guidance.
Guardant Health (NASDAQ: GH) insider files to sell 1,700 shares
Manuel Hidalgo Medina, an insider at Guardant Health (NASDAQ: GH), has filed a Form 144 indicating an intent to sell up to 1,700 shares of common stock through Charles Schwab & Co., Inc. The proposed sale, valued at $279,202.00, is supported by upcoming restricted stock lapses and an employee stock option exercise. The filing also notes prior sales by Medina of 1,250 shares on May 20, 2026, and 1,000 shares on May 28, 2026.
Guardant Health (GH) insider files to sell 1,803,685 shares valued at $134M
An insider at Guardant Health (GH), Meghan V. Joyce, has filed a notice to sell up to 1,803,685 shares of common stock, valued at approximately $134 million, through Charles Schwab & Co., Inc. The proposed sale date is August 5, 2026, on NASDAQ. The filing also details several sales made by Joyce over the prior three months, totaling 24,203 shares.
Guardant Health (GH) Sees 48% Growth as Its Cancer Tests Gain Momentum
Guardant Health (GH) experienced a 48% year-over-year revenue growth in Q1 2026, driven by strong adoption of its Guardant360 cancer treatment selection test and the Shield colorectal cancer blood test. Baron Capital's Q2 2026 investor letter highlighted Guardant Health's potential, noting its positioning for positive free cash flow. The company's stock has seen a 258.35% gain over the past 52 weeks, with a market capitalization of $21.44 billion.
Guardant Health (GH) Sees 48% Growth as Its Cancer Tests Gain Momentum
Guardant Health (NASDAQ:GH) experienced 48% revenue growth year-over-year, driven by increased adoption of its Guardant360 cancer treatment selection test and the Shield colorectal cancer blood test. The company's prospects are further boosted by the FDA approval of Guardant360 Liquid CDx and the American Cancer Society's recommendation of Shield, positioning it for positive free cash flow. This information was highlighted in Baron Capital's Q2 2026 investor letter for its Baron Health Care Fund.
GUARDANT HEALTH INC : PIPER SANDLER RAISES TARGET PRICE TO $193.00 FROM $135.00
Piper Sandler has increased its target price for Guardant Health Inc. (GH.O) shares to $193.00 from $135.00. This news was reported by Reuters on August 4, 2026. The article reiterates that the content reflects only the author's opinion and is not investment advice.
Guardant Health (GH) insider Ian T. Clark plans potential sale of 14,180 shares
Guardant Health (GH) insider Ian T. Clark has filed a Form 144 notice for a proposed sale of 14,180 shares of common stock, valued at approximately $2,253,450.00. The sale is planned for around August 4, 2026, through Charles Schwab & Co., Inc. on NASDAQ. This filing follows a previous sale of 6,876 shares by Clark in May 2026 and is linked to restricted stock lapse and employee stock option exercise events.
Guardant Health (GH) Filed A Shelf Registration To Keep Future Funding Options Open
Guardant Health (GH) has filed a universal shelf registration statement, granting it the flexibility to issue various securities in the future. This move enables the company to raise capital through debt, equity, or hybrid instruments, potentially supporting future financing, acquisitions, or balance sheet adjustments. While the filing doesn't commit Guardant Health to immediate fundraising, it provides a mechanism for rapid capital raising should market conditions or corporate priorities warrant it.
GUARDANT HEALTH INC : PIPER SANDLER RAISES TARGET PRICE TO $193.00 FROM $135.00
Piper Sandler has increased its target price for Guardant Health Inc. (GH.O) shares to $193.00 from the previous $135.00. This adjustment indicates a significantly more optimistic outlook for the company's stock by the analyst firm.
Guardant Health Price Target Raised to $180.00/Share From $130.00 by Stifel
Stifel has raised its price target for Guardant Health (NASDAQ:GH) from $130.00 to $180.00 per share. This indicates a significant increase in the analyst's valuation of the company's stock.
Guardant Health Earnings: Shield Momentum Shows No Signs Of Slowing, Guidance Raised Again
Guardant Health reported strong second-quarter results, with 44% revenue growth and a 50% sequential increase in Shield colorectal cancer screening tests. Following this performance, management raised its full-year revenue guidance to $1.35 billion at the midpoint, marking a 3% increase from previous guidance. This indicates continued momentum for the company's screening products.
Guardant Health (GH) Stock Jumps As Shield Growth Masks Loss Pressure
Guardant Health (GH) stock increased by 6.3% despite widening losses, as Q2 revenue grew 44% to US$335 million, driven significantly by Shield testing, which saw a more than threefold increase in revenue and test volumes. The market is focusing on the growth story and Shield momentum, even as the company continues to report substantial net losses and operates with a high P/S multiple of 18.4x. While management raised revenue guidance for the full year and reaffirmed a cash flow breakeven target by the end of 2027, concerns about cash burn and rising operating expenses persist.
Guardant Health Leads the Way in Blood-Based Single Cancer Screening
Guardant Health is positioned as a leader in liquid biopsy, offering market-leading platforms in tumor genomic profiling, molecular residual disease (MRD) testing, and colorectal cancer screening. Despite promising markets with multi-billion dollar revenue potential, the company faces early-stage uncertainties regarding payer coverage and guideline inclusion. Morningstar analysts do not anticipate Guardant Health to achieve positive cash flows until 2028.
Guardant Health, Inc. Stock 12‑Month Price Target Raised to $191.09, Implies 25% Upside
Analysts have raised the average 12-month price target for Guardant Health, Inc. (GH) stock to $191.09, up from $177, with forecasts spanning $125 to $225 per share. This new target suggests a potential upside of approximately 25% from its July 30th closing price. The consensus rating from 29 analysts remains a "Buy," with 25 recommending Buy, 2 Hold, and 2 Sell.
Is Guardant Health Inc (GH) Overvalued After Q2 Earnings Miss? E
Guardant Health Inc (GH) reported a strong Q2 2026 revenue growth of 44% to $335.0 million, driven by oncology and a surging screening division, but net losses widened to $120.1 million due to increased operational expenses. Despite raising 2026 revenue guidance, GuruFocus deems the stock significantly overvalued at $152.35 against a GF Value of $61.69, highlighting concerns about financial strength and profitability despite high growth potential. Insider selling further suggests a cautious outlook on the company's current valuation.
Guardant Health stock rises after guidance hike (GH:NASDAQ)
Guardant Health (GH) stock rose nearly 10% and hit a new 52-week high after reporting Q2 2026 revenue that significantly beat consensus estimates. The blood-based cancer test maker also raised its full-year outlook, with its oncology portfolio growing 38% year-over-year and screening revenue seeing substantial increases. Analysts suggest that the current share price does not fully reflect the company's strong momentum and leading position in the liquid biopsy market.
Guardant Health, Inc. Stock 12‑Month Price Target Raised to $180.91, Implies 19% Upside
Guardant Health, Inc.'s stock's 12-month average price target has been raised from $174.61 to $180.91, based on estimates from 23 analysts, implying a 19% potential upside from the Jul. 30 closing price. The consensus rating remains "Buy" among 29 covering analysts, with the majority recommending a purchase. This updated target indicates continued analyst confidence in the company's future performance.
Guardant Health earnings on deck after catalyst-rich quarter
Guardant Health (GH) is set to release its Q2 earnings on Thursday, with investors focusing on the impact of recent commercial and regulatory catalysts. Analysts expect a loss of 76 cents per share on revenue of $314.3 million, with Wall Street maintaining an overwhelmingly bullish stance on the stock. Key areas of investor interest include Shield test volumes, management commentary on early adoption, guidance revisions, and the timeline for G360 average selling price improvements.
How Investors Are Reacting To Guardant Health (GH) Spotlighting Shield Test And Teeing Up Earnings
Guardant Health is gaining investor attention following a colorectal cancer screening awareness campaign featuring Patrick Dempsey for its FDA-approved Shield blood test and ahead of its upcoming quarterly earnings report. The Shield test is the only FDA-approved blood test included in major colorectal cancer screening guidelines, positioning Guardant Health uniquely in the non-invasive screening market. The upcoming earnings report, expected after previous revenue surpassed analyst expectations, will be crucial in determining if the increased focus on Shield translates into sustainable revenue growth to support the company's valuation and spending.
